Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P53007: Variant p.Gly130Asp

Tricarboxylate transport protein, mitochondrial
Gene: SLC25A1
Feedback?
Variant information Variant position: help 130 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glycine (G) to Aspartate (D) at position 130 (G130D, p.Gly130Asp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to medium size and acidic (D) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In D2L2AD; severely reduced rates of citrate transport. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 130 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 311 The length of the canonical sequence.
Location on the sequence: help NHMRDAQGRLDSTRGLLCGL G AGVAEAVVVVCPMETIKVKF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         NHMRDAQ-GRLDSTRGLLCGLGAGVAEAVVVVCPMETIKVKF

Mouse                         NHMRDAQ-GRLDSRRGLLCGLGAGVAEAVVVVCPMETIKVK

Rat                           NHMRDAQ-GRLDSRRGLLCGLGAGVAEAVVVVCPMETVKVK

Bovine                        NHMRDAQ-GRLDSTRGLLCGLGAGVPEAVVVVCPMETIKVK

Caenorhabditis elegans        SQAADER-GNLSPVMRLLCGLGAGLSEAVFAVTPMETVKVK

Baker's yeast                 DMLRDSETGELSGTRGVIAGLGAGLLESVAAVTPFEAIKTA

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 14 – 311 Tricarboxylate transport protein, mitochondrial
Transmembrane 129 – 143 Helical; Name=3
Repeat 122 – 208 Solcar 2



Literature citations
Pathogenic mutations of the human mitochondrial citrate carrier SLC25A1 lead to impaired citrate export required for lipid, dolichol, ubiquinone and sterol synthesis.
Majd H.; King M.S.; Smith A.C.; Kunji E.R.S.;
Biochim. Biophys. Acta 1859:1-7(2018)
Cited for: FUNCTION; TRANSPORTER ACTIVITY; BIOPHYSICOCHEMICAL PROPERTIES; CHARACTERIZATION OF VARIANTS D2L2AD LEU-45; ASP-130; GLN-144; TRP-193; HIS-198; THR-202; CYS-282; GLY-282; HIS-282 AND CYS-297; CHARACTERIZATION OF VARIANT CMS23 GLN-247; Agenesis of corpus callosum and optic nerve hypoplasia due to mutations in SLC25A1 encoding the mitochondrial citrate transporter.
Edvardson S.; Porcelli V.; Jalas C.; Soiferman D.; Kellner Y.; Shaag A.; Korman S.H.; Pierri C.L.; Scarcia P.; Fraenkel N.D.; Segel R.; Schechter A.; Frumkin A.; Pines O.; Saada A.; Palmieri L.; Elpeleg O.;
J. Med. Genet. 50:240-245(2013)
Cited for: VARIANTS D2L2AD ASP-130 AND HIS-282;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.